Breaking News
13 hours ago
Vaibhavi M.
Pfizer reports Phase 3 BASIS data showing HYMPAVZI significantly reduced bleeding in hemophilia A and B patients with inhibitors.
Vaibhavi M.
Regeneron presents Phase 1/2 data showing Lynozyfic delivers rapid, deep responses in newly diagnosed multiple myeloma at the ASH Annual Meeting.
Vaibhavi M.
Sandoz completes acquisition of Evotec’s Toulouse biologics site, boosting continuous manufacturing capabilities and strengthening its global biosimilars strategy.
Vaibhavi M.
Praxis secures FDA alignment in its pre-NDA meeting and prepares a 2026 NDA submission for ulixacaltamide, a potential new therapy for essential tremor.
Vaibhavi M.